Pfizer 8-K
CEO/CFO change
Dave Denton leaves for a consumer-goods opportunity; Cecile Guegan becomes interim CFO as Pfizer searches for a successor.
Filed 2026-06-18 07:07 ET
- 5.02 Officer/director change
- 9.01 Financial Statements and Exhibits
Summary
CFO transition. Dave Denton will leave Pfizer on 08/15/2026 for a consumer-goods opportunity outside the pharmaceutical industry. Cecile Guegan, currently senior vice president of finance for the Global Biopharmaceutical Business, becomes interim CFO on 08/16/2026 while Pfizer conducts an internal and external search for a successor. Denton said his departure is unrelated to Pfizer’s financial or operating results or any disagreement with the company.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3